Two strengths, one connected path forward. With MCRA now part of IQVIA MedTech, innovators can access regulatory expertise and clinical and commercialization capabilities in one trusted place. Hear from Kelley Kennedy and Glenn Stiegman on what this means in practice. https://bit.ly/4fJr3wu
IQVIA MedTech
Medical Equipment Manufacturing
Global Partner for accelerating MedTech innovation
About us
IQVIA MedTech is the only dedicated partner built to help MedTech innovators thrive — from first milestone to market impact. We bring together deep therapeutic expertise, regulatory strength, and commercial insight with unmatched data and technology to accelerate smarter decisions, reduce risk, and unlock long-term value. Whether you're navigating early development, scaling globally, or optimising post-market performance, our purpose-built teams and modular solutions flex to meet your needs. With global infrastructure, local precision, and a proven track record across 80+ countries, IQVIA MedTech empowers you to move with confidence — and thrive in market. Learn more at http://www.iqviamedtech.com.
- Website
-
http://iqviamedtech.com
External link for IQVIA MedTech
- Industry
- Medical Equipment Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- New York
- Founded
- 2016
- Specialties
- Medical Devices and Diagnostics, MedTech, IVD, Commercial, Full clinical Trials, Legal/Compliance/Risk Management, Recall, Global Data and Analytics, Consulting, Primary Market Research, Quality Management, Master Data Management, Regulatory Strategy, Consulting, Management, and Outsourcing (Technical, Clinical, Sales, Field, Inside Sales)
Updates
-
Point-of-Care High-Sensitivity Troponin (POC hsTn) is at an inflection point, and the companies that stand to gain are the ones who understand where the market is forming and how to capture it. But anecdotal insight won't get you there. In this blog, our experts explain how a disciplined, data-driven commercial strategy can help you turn momentum into market advantage. Read now: https://lnkd.in/epnjD_Ca
-
-
Scaling and maintaining field operations is complex. IQVIA MedTech has proven expertise: • 450+ field service professionals • 15 of the top 20 MedTech players use our field services • 4.8 latest customer satisfaction rating on a scale of 5 See how leading MedTech organizations scale teams and sustain performance. Access brochure and case studies: https://lnkd.in/eVyGJdZk
-
Some decisions are easier to make when you can talk them through. At ADLM 2026, connect with IQVIA MedTech to explore options in the IVD space across clinical trials, regulatory submissions, and market access. Join us at booth 4137 in Anaheim or book a meeting that fits your schedule here: https://bit.ly/4gL8KrE
-
From Medtronic’s Hugo securing FDA clearance for urologic procedures to HistoSonics’ $250M financing for incisionless histotripsy, surgical robotics is shifting into a complex and competitive marketplace. Here, IQVIA MedTech’s Kyle Biesecker, Ph.D. discusses 2026 as a pivotal window for new product entry and use case expansion. Read his insights, and more, in our latest blog: https://lnkd.in/e6fzcAYk
-
-
What trends are shaping the global in vitro diagnostics market? Join IQVIA MedTech at the ADLM 2026 International Market Briefing, where David Kowalski, Principal and Global Head of IVD Consulting, will provide an update on the key developments influencing IVD markets worldwide. Learn more and register: https://lnkd.in/d-kBYZpe
-
-
A lot of IVD challenges come from how decisions connect across teams. In this session, experts form IQVIA MedTech and MCRA bring together perspectives across regulatory, reimbursement, clinical evidence and market strategy, with practical examples of what alignment looks like in practice. Watch on-demand here: https://bit.ly/4a9Jh79
-
-
2026 is poised to be a year of global regulatory harmonization – with legacy compliance systems giving way to future-looking FDA programs. In our 2026 trends piece, IQVIA MedTech’s Julie Larsen considers the opportunities and complexities of this shift, offering practical tips on navigating the changes with confidence. Read now: https://lnkd.in/dHdEySxP
-
-
The FDA’s December 2025 update to its medical device RWE guidance document formalizes an evolving regulatory approach for MedTech sponsors. The revised guidance document clarifies that high quality RWE can support regulatory submissions even when identifiable participant level data are not directly accessible provided sponsors can demonstrate data relevance, reliability, and traceability. This added flexibility does not lower evidentiary standards. Instead, it raises expectations around documentation, data quality assessments, and transparency in how RWD are curated and used. For MedTech sponsors, the update underscores the importance of fit for purpose RWD and the importance of early engagement to align on data strategy. Learn more about what this means for your RWE strategy in our latest blog: https://bit.ly/4baEG4n
-
-
Point-of-Care High-Sensitivity Troponin (POC hsTn) is at an inflection point, and the companies that stand to gain are the ones who understand where the market is forming and how to capture it. But anecdotal insight won't get you there. In this blog, our experts explain how a disciplined, data-driven commercial strategy can help you turn momentum into market advantage. Read now: https://lnkd.in/epnjD_Ca
-